The Cl0p Ransomware Gang's Attack on AbbVie

The Cl0p ransomware gang has attacked Abbvie. AbbVie is a global biopharmaceutical company that specializes in the development and commercialization of pharmaceuticals and healthcare products. It was founded in 2013 as a spin-off from Abbott Laboratories. AbbVie is known for its focus on research and development in the areas of immunology, oncology, virology, neuroscience, and other therapeutic areas. Cl0p posted Abbvie to its data leak site on June 27th but provided no further details.

Background on Cl0p

Cl0p is a RaaS platform first observed in 2019. Cl0p has advanced anti-analysis capabilities and anti-virtual machine analysis to prevent investigations in an emulated environment like those commonly used by security tools. Cl0p is increasingly using automation to exploit known vulnerabilities to infiltrate targets, as well as a SQL injection zero-day vulnerability (CVE-2023-34362) that installs a web shell – a rarity amongst ransomware operators.

Recent Surge in Attacks

Attacks by Cl0p surged in Q1 of 2023 as the gang leveraged patchable exploits for the GoAnywhere file transfer software to compromise more than 100 victims in a matter of weeks, although it is unknown how well they were able to monetize the attacks. Cl0p is likely to be leveraging automation to identify exposed organizations who have not patched against known vulnerability, which is why we are seeing so many new victims.

Ransom Demands

Ransom demands vary depending on the target and average around $3 million dollars but have been reported as to be as high as $20 million. Ransom amounts are likely to continue to grow as Clop focuses more on the exfiltration of sensitive data.